PD-(L)1 market

Mar 07, 2025

On March 3, 2025, BeiGene secured another approval for its anti-PD-1 antibody, TEVIMBRA, as the FDA granted clearance for its use in combination with platinum-based chemotherapy as a first-line treatment for adults with unresectable or metastatic esophageal squamous cell carcinoma (ESCC) whose tumors express PD-L1....

Jun 14, 2024

Bristol Myers Squibb’s PD-1 inhibitor, OPDIVO, has deep roots in Japan. In July 2014, MHLW approved OPDIVO to treat melanoma, marking it the first approved PD-1 inhibitor globally. About two years later, KEYTRUDA gained approval in Japan for the same indications (melanoma and NSCLC). This set the stage for fierce c...

May 31, 2024

The advent of PD-(L)1 inhibitors marks a monumental shift in the landscape of cancer treatment. These agents have redefined the therapeutic approach to several malignancies, offering hope where traditional therapies often fell short. PD-(L)1 inhibitors are a class of drugs that block the interaction between the pro...